AR105080A1 - Compuestos inhibidores de la señalización de la vía de notch - Google Patents
Compuestos inhibidores de la señalización de la vía de notchInfo
- Publication number
- AR105080A1 AR105080A1 ARP160101848A ARP160101848A AR105080A1 AR 105080 A1 AR105080 A1 AR 105080A1 AR P160101848 A ARP160101848 A AR P160101848A AR P160101848 A ARP160101848 A AR P160101848A AR 105080 A1 AR105080 A1 AR 105080A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- signaling
- loss
- inhibiting compounds
- hair cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud proporciona compuestos, o una sal farmacéuticamente aceptable de estos y una composición farmacéutica que contiene dichos compuestos o una sal farmacéuticamente aceptable de esta, útil como un inhibidor de la señalización de la vía Notch para el tratamiento de los cánceres nombrados, pérdida de audición neurosensorial causada por la pérdida de células ciliadas auditivas e inducción de la generación de células ciliadas auditivas. Reivindicación 1: Un compuesto de la estructura de fórmula (1), 4,4,4-trifluoro-N-((2S)-1-((9-metoxi-3,3dimetil-5-oxo-2,3,5,6-tetrahidro-1H-benzo[f]pirrolo[1,2-a]azepin-6-il)amino)-1-oxopropan-2-il)butanamida, uno de sus isómeros puro en forma sustancialmente diastereomérica o una sal farmacéuticamente aceptable de cualquiera de los anteriores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189393P | 2015-07-07 | 2015-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105080A1 true AR105080A1 (es) | 2017-09-06 |
Family
ID=56507825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101848A AR105080A1 (es) | 2015-07-07 | 2016-06-21 | Compuestos inhibidores de la señalización de la vía de notch |
Country Status (42)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2892506B1 (en) | 2012-09-07 | 2021-11-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss with the gamma-secretase inhibitor ly411575 |
| AR105080A1 (es) | 2015-07-07 | 2017-09-06 | Lilly Co Eli | Compuestos inhibidores de la señalización de la vía de notch |
| CN109689027A (zh) | 2016-06-29 | 2019-04-26 | 奥德纳米有限公司 | 甘油三酯耳用制剂及其用途 |
| US11253193B2 (en) * | 2016-11-08 | 2022-02-22 | Cochlear Limited | Utilization of vocal acoustic biomarkers for assistive listening device utilization |
| WO2018111926A2 (en) | 2016-12-16 | 2018-06-21 | Inception 3, Inc. | Methods of treating cochlear synaptopathy |
| AU2018237987B2 (en) * | 2017-03-24 | 2021-01-21 | Novartis Ag | Isoxazole carboxamide compounds and uses thereof |
| WO2020016855A1 (en) * | 2018-07-20 | 2020-01-23 | The Hong Kong Polytechnic University | Peptides for specific inhibition of jag1-notch1 pathway |
| MA53645A (fr) * | 2018-09-21 | 2021-12-29 | Novartis Ag | Composés d'isoxazole carboxamide et leurs utilisations |
| KR20210084484A (ko) | 2018-10-02 | 2021-07-07 | 프리퀀시 테라퓨틱스, 인크. | 귀 치료제를 포함하는 약제학적 조성물 및 관련 방법 |
| WO2020112883A1 (en) * | 2018-11-30 | 2020-06-04 | Massachusetts Eye And Ear Infirmary | Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells |
| WO2020210388A1 (en) | 2019-04-08 | 2020-10-15 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
| WO2021150672A2 (en) * | 2020-01-22 | 2021-07-29 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for placenta accreta spectrum (pas) disorders |
| EP4281456A4 (en) * | 2021-01-20 | 2025-01-01 | Prism Biolab Co Ltd | NEW BICYCLIC COMPOUNDS |
| EP4508052A1 (en) * | 2022-04-11 | 2025-02-19 | PRISM BioLab Co., Ltd. | Novel seven-membered ring-fused compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
| AU2007229550B2 (en) | 2006-03-27 | 2012-03-08 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma secretase inhibitors |
| US8188131B2 (en) | 2008-02-07 | 2012-05-29 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh1 expression |
| US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| US10143711B2 (en) | 2008-11-24 | 2018-12-04 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| WO2012047706A2 (en) | 2010-10-06 | 2012-04-12 | Massachusetts Eye & Ear Infirmary | Methods for promotiing reinnervation of auditory hair cells |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| US8716229B2 (en) | 2011-11-09 | 2014-05-06 | Massachusetts Eye & Ear Infirmary | Osteoprotegerin in neuroprotection |
| EP2892506B1 (en) * | 2012-09-07 | 2021-11-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss with the gamma-secretase inhibitor ly411575 |
| AU2013337422A1 (en) | 2012-11-02 | 2015-05-07 | Genesys Research Institute | Compositions and methods for auditory therapy |
| AR105080A1 (es) | 2015-07-07 | 2017-09-06 | Lilly Co Eli | Compuestos inhibidores de la señalización de la vía de notch |
| WO2018111926A2 (en) * | 2016-12-16 | 2018-06-21 | Inception 3, Inc. | Methods of treating cochlear synaptopathy |
-
2016
- 2016-06-21 AR ARP160101848A patent/AR105080A1/es active IP Right Grant
- 2016-06-21 TW TW105119456A patent/TWI625332B/zh active
- 2016-06-21 JO JOP/2016/0125A patent/JO3491B1/ar active
- 2016-07-01 CR CR20220368A patent/CR20220368A/es unknown
- 2016-07-01 CA CA2987431A patent/CA2987431C/en active Active
- 2016-07-01 ME MEP-2019-191A patent/ME03495B/me unknown
- 2016-07-01 WO PCT/US2016/040612 patent/WO2017007702A1/en active Application Filing
- 2016-07-01 UA UAA201712094A patent/UA120539C2/uk unknown
- 2016-07-01 TN TNP/2017/000495A patent/TN2017000495A1/en unknown
- 2016-07-01 EA EA201792478A patent/EA032634B1/ru not_active IP Right Cessation
- 2016-07-01 RS RS20190820A patent/RS59115B1/sr unknown
- 2016-07-01 HU HUE16741742 patent/HUE044666T2/hu unknown
- 2016-07-01 CN CN201680039699.XA patent/CN107849054B/zh active Active
- 2016-07-01 DK DK16741742.7T patent/DK3319967T3/da active
- 2016-07-01 MY MYPI2018700032A patent/MY197519A/en unknown
- 2016-07-01 KR KR1020187000149A patent/KR102078946B1/ko active Active
- 2016-07-01 EP EP16741742.7A patent/EP3319967B1/en active Active
- 2016-07-01 CR CR20170598A patent/CR20170598A/es unknown
- 2016-07-01 LT LTEP16741742.7T patent/LT3319967T/lt unknown
- 2016-07-01 PT PT16741742T patent/PT3319967T/pt unknown
- 2016-07-01 AU AU2016289822A patent/AU2016289822B2/en active Active
- 2016-07-01 NZ NZ737322A patent/NZ737322A/en unknown
- 2016-07-01 SI SI201630270T patent/SI3319967T1/sl unknown
- 2016-07-01 TR TR2019/08683T patent/TR201908683T4/tr unknown
- 2016-07-01 US US15/736,345 patent/US10450317B2/en active Active
- 2016-07-01 MD MDE20180506 patent/MD3319967T2/ro unknown
- 2016-07-01 MA MA42399A patent/MA42399B1/fr unknown
- 2016-07-01 PE PE2018000012A patent/PE20180412A1/es unknown
- 2016-07-01 ES ES16741742T patent/ES2735139T3/es active Active
- 2016-07-01 PL PL16741742T patent/PL3319967T3/pl unknown
- 2016-07-01 MX MX2017016555A patent/MX376082B/es active IP Right Grant
- 2016-07-01 JP JP2017568395A patent/JP6571214B2/ja active Active
-
2017
- 2017-11-16 IL IL255726A patent/IL255726B/en active IP Right Grant
- 2017-11-20 ZA ZA2017/07858A patent/ZA201707858B/en unknown
- 2017-12-20 SV SV2017005597A patent/SV2017005597A/es unknown
-
2018
- 2018-01-02 CL CL2018000007A patent/CL2018000007A1/es unknown
- 2018-01-02 EC ECIEPI201842A patent/ECSP18000042A/es unknown
- 2018-01-05 DO DO2018000005A patent/DOP2018000005A/es unknown
- 2018-01-05 PH PH12018500047A patent/PH12018500047B1/en unknown
- 2018-01-12 CO CONC2018/0000224A patent/CO2018000224A2/es unknown
- 2018-05-17 HK HK18106380.5A patent/HK1247187B/zh unknown
-
2019
- 2019-06-28 HR HRP20191175TT patent/HRP20191175T1/hr unknown
- 2019-07-23 CY CY20191100776T patent/CY1122024T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105080A1 (es) | Compuestos inhibidores de la señalización de la vía de notch | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| MX2020004932A (es) | Compuestos utiles para inhibir a cdk7. | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| CL2013003160A1 (es) | Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros. | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CL2015002649A1 (es) | Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| CR20140216A (es) | 5,7-imidazo[1,2-c]pirimidinas sustituidas | |
| UY34062A (es) | ?compuestos heterocíclicos fusionados moduladores de canal ionico para el tratamiento de enfermedades que responden al bloqueo de canal de sodio?. | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PE20151501A1 (es) | Inhibidores de prmt5 y sus usos | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| SV2011003997A (es) | Pirimidinas fusionadas | |
| CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| GT201200004A (es) | Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria | |
| CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
| CL2016000496A1 (es) | Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias. | |
| CL2017002449A1 (es) | Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
| EA201400001A1 (ru) | Новые производные фталазинонпирролопиримидинкарбоксамида | |
| CO2017003225A2 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos | |
| CU20140127A7 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| UY35792A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |